The mechanistic role of epigenetic in multiple myeloma

被引：0

作者：

Hajizamani S. ^{[1
]}

Golchin N. ^{[1
]}

Shahjahani M. ^{[1
]}

Tamaddon G.H. ^{[2
]}

Vosoughi T. ^{[1
]}

Yousefi H. ^{[1
]}

Saki N. ^{[1
]}

机构：

[1] Health Research Institute, Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz

[2] Research Center of Cancer, Shiraz University of Medical Sciences, Shiraz

来源：

Comparative Clinical Pathology | 2016年 / 25卷 / 6期

关键词：

Apoptosis; CD markers; Cell cycle; DNA repair system; Epigenetic modifications; miRNA; Multiple myeloma; Signaling pathway;

D O I：

10.1007/s00580-015-2074-3

中图分类号：

学科分类号：

摘要：

Multiple myeloma (MM) is a B cell malignancy characterized by accumulation of malignant plasma cells in the bone marrow. Pathogenesis of MM involves a complex pattern of structural and numerical chromosomal aberrations. In addition, epigenetic changes such as DNA methylation and histone modifications may play a role in this disease by affecting the expression of different genes. This article reviews recent findings on the role of epigenetic alterations in MM pathogenesis, which affect the expression of cell cycle regulatory molecules, apoptosis, DNA repair system, CD markers, cell signaling pathways as well as tumor suppressor miRNAs. Given these results, it can be stated that these epigenetic changes play an important role in the initiation and progression of MM. Therefore, understanding the impact of epigenetics in MM pathogenesis in each stage of disease progression can help develop therapeutic targets to increase survival and reduce drug resistance. © 2015, Springer-Verlag London.

引用

页码：1279 / 1288

页数：9

共 62 条

[1]

Abroun S., Saki N., Fakher R., Asghari F., Biology and bioinformatics of myeloma cell, Lab Hematol Off Publ Int Soc Lab Hematol, 18, 4, pp. 30-41, (2012)

[2]

Barrena S., Almeida J., Yunta M., Lopez A., Fernandez-Mosteirin N., Giralt M., Et al., Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation, Leukemia, 19, 8, pp. 1376-1383, (2005)

[3]

Benetatos L., Dasoula A., Hatzimichael E., Georgiou I., Syrrou M., Bourantas K.L., Promoter hypermethylation of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma, Clin Lymphoma Myeloma, 8, 3, pp. 171-175, (2008)

[4]

Bovolenta P., Esteve P., Ruiz J.M., Cisneros E., Lopez-Rios J., Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease, J Cell Sci, 121, 6, pp. 737-746, (2008)

[5]

Cea M., Cagnetta A., Gobbi M., Patrone F., Richardson P.G., Hideshima T., Et al., New insights into the treatment of multiple myeloma with histone deacetylase inhibitors, Curr Pharm Des, 19, 4, pp. 734-744, (2013)

[6]

Chen G., Wang Y., Huang H., Lin F., Wu D., Sun A., Et al., Combination of DNA methylation inhibitor 5‐azacytidine and arsenic trioxide has synergistic activity in myeloma, Eur J Haematol, 82, 3, pp. 176-183, (2009)

[7]

Chesi M., Bergsagel P.L., Epigenetics and microRNAs combine to modulate the MDM2/p53 axis in myeloma, Cancer Cell, 18, 4, pp. 299-300, (2010)

[8]

Chim C., Fung T., Liang R., Disruption of INK4/CDK/Rb cell cycle pathway by gene hypermethylation in multiple myeloma and MGUS, Leukemia, 17, 12, pp. 2533-2535, (2003)

[9]

Chim C.-S., Fung T.-K., Cheung W.-C., Liang R., Kwong Y.-L., SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway, Blood, 103, 12, pp. 4630-4635, (2004)

[10]

Chim C., Liang R., Fung T., Kwong Y., Infrequent epigenetic dysregulation of CIP/KIP family of cyclin-dependent kinase inhibitors in multiple myeloma, Leukemia, 19, 12, pp. 2352-2355, (2005)

← 1 2 3 4 5 6 7 →